

Curriculum Vitae

Personal information **Paolo Antonio Ascierto**

Work experience

1. Employer: Faculty of Medicine and Surgery, University of Naples
 - Start date: 1988
 - End date: 1990
 - Position: • Graduate student at the Department of Medical Oncology
 - Activities:
 - Country: Italy
2. Employer: Faculty of Medicine and Surgery, University
 - Start date: 1990
 - End date: 1991
 - Position: • Postdoctoral Guest at the Department of Medical Oncology
 - Activities:
 - Country: Italy
3. Employer: Istituto Nazionale Tumori IRCCS Pascale of Napoli
 - Start date: 1991
 - End date: 1993
 - Position: Postdoctoral fellow
 - Activities:
 - Country: Italy
4. Employer: Istituto Nazionale Tumori IRCCS Pascale of Napoli
 - Start date: 1993
 - End date: 2008
 - Position: • Vice Director at the Department of Clinical Immunology
 - Activities:
 - Country: Italy
5. Employer: Istituto Nazionale Tumori IRCCS Pascale of Napoli
 - Start date: 032008
 - End date: 072011
 - Position: • Director at the Unit of Medical Oncology and Innovative Therapy
 - Activities:
 - Country: Italy
6. Employer: Istituto Nazionale Tumori IRCCS Pascale of Napoli
 - Start date: 082011
 - End date: 072013
 - Position: • Vice_Director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy
 - Activities:
 - Country: Italy
7. Employer: Istituto Nazionale Tumori IRCCS Pascale of Napoli
 - Start date: 082013
 - End date:
 - Position: • Permanent position as Director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy
 - Activities:
 - Country: Italy
8. Employer: Istituto Nazionale Tumori IRCCS Pascale of Napoli
 - Start date: 042020
 - End date:
 - Position: Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics
 - Activities:
 - Country: Italy

Education and training

1. Subject: University of Naples Federico II
 - Start date: 101983
 - End date: 071990
 - Qualification: MD Medicine and Surgery
 - Organisation:
 - Country: Italy
2. Subject: University of Naples Federico II
 - Start date: 021991
 - End date: 071994
 - Qualification: Board Oncology
 - Organisation:
 - Country: Italy

Additional information

Publications

Relevant Publications (last 5 years): Ascierto PA, Streicher HZ, Sznol M. Melanoma: A model for testing new agents in combination therapies. *J Transl Med.* 2010; 8:38. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al; the BRIM_3 Study Group. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. *N Engl J Med.* 2011 Jun 5. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. *J Transl Med.* 2012 Jan 3;10:1. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, et al. Defining the Critical Hurdles in Cancer Immunotherapy. *J Transl Med.* 2011 Dec 14;9(1):214. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA, Palmieri G. BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. *J Clin Oncol.* 2012 May 21. [Epub ahead of print] Ascierto PA, Simeone E, Giannarelli D, et al. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. *J Transl Med.* 2012 May 28;10(1):107. Lebbe C, Lorigan P, Ascierto P, Testori A, Bédane C, Middleton M, van Baardewijk M, Konto C, Dueymes A, Maio M. Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study). *Eur J Cancer.* 2012 Jun 26. [Epub ahead of print]. Ascierto PA, Gogas HJ, Grob JJ, Algarra SM, Mohr P, Hansson J, Hauschild A. Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review. *Crit Rev Oncol Hematol.* 2012 Aug 5. [Epub ahead of print]. Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT_M1): an open_label, single_arm phase 2 trial. *Lancet Oncol.* 2012 Sep;13(9):879-86.. Ascierto PA. MEK inhibition in BRAF_mutated melanoma. *N Engl J Med.* 2012 Oct 4;367(14):1364. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF_mutant melanoma metastatic to the brain (BREAK_MB): a multicentre, open_label, phase 2 trial. *Lancet Oncol.* 2012 Nov;13(11):1087-95. Ascierto PA, Minor D, Ribas A, et al. Phase II Trial (BREAK_2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. *J Clin Oncol.* 2013 Aug 5. Ascierto PA, Kalos M, Schaefer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. *Clin Cancer Res.* 2013 Mar 1;19(5):1009-20. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non_randomised, open_label phase 2 study. *Lancet Oncol.* 2013 Mar;14(3):249-56. Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J, Fox BA. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. *J Transl Med.* 2013 Mar 3;11:54. Ascierto PA, Simeone E, Grimaldi AM, Curvietto M, Esposito A, Palmieri G, Mozzillo N. Do BRAF inhibitors select for populations with different disease progression kinetics? *J Transl Med.* 2013 Mar 8;11:61. Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK_2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. *J Clin Oncol.* 2013 Sep 10;31(26):3205-11. Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, Aamdal S, Ascierto PA, et al. djuvant ganglioside GM2_KLH/QS_21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. *J Clin Oncol.* 2013 Oct 20;31(30):3831-7. Maio M, Danielli R, Chiarion_Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto PA. Efficacy and safety of ipilimumab in patients with pre_treated, uveal melanoma. *Ann Oncol.* 2013 Nov;24(11):2911-5. Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabrò L, Maio M. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. *Eur J Cancer.* 2014 Jan;50(1):121-7. Galon J, Mlecnik B, Bindea G, ..., Ascierto PA, Marincola FM, Fox BA, Pagès F. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. *J Pathol.* 2014 Jan;232(2):199-209. Grimaldi AM, Simeone E, Ascierto PA. The role of MEK inhibitors in the treatment of metastatic melanoma. *Curr Opin Oncol.* 2014 Jan 13. [Epub ahead of print] PubMed PMID: 24419498. Ascierto PA, Simeone E, Sileni VC, et al. Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. *Cancer Invest.* 2014 Apr;32(4):144-9. Flaherty KT, Hennis M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, Robert C, Schadendorf D. Surrogate endpoints for overall survival in metastatic melanoma: a meta_analysis of randomised controlled trials. *Lancet Oncol.* 2014 Mar;15(3):297-304. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation_positive melanoma (BRIM_3): extended follow_up of a phase 3, randomised, open_label study. *Lancet Oncol.* 2014 Mar;15(3):323-32. Ascierto PA, Margolin K. Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma. *Cancer.* 2014 Feb 27. doi: 10.1002/cncr.28622. [Epub ahead of print] PubMed PMID: 24577788. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hossers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open_label, multicentre, safety study. *Lancet Oncol.* 2014 Apr;15(4):436-44. Chiarion_Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, Marchetti P, De Galitiis F, Testori A, Ferrucci PF, Queirolo P, Spagnolo F, Quaglini P, Carnevale Schianca F, Mandalà M, Di Guardo L, Del Vecchio M. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. *Br J Cancer.* 2014 Apr 1;110(7):1721-6. Simeone E, Gentilecore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. *Cancer Immunol Immunother.* 2014 Apr 3. [Epub ahead of print] PubMed PMID: 24695951. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF_mutated melanoma. *N Engl J Med.* 2014; 371:1867-76. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka_Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalciou C, Chiarion_Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren_Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. *N Engl J Med.* 2014 Nov 16. [Epub ahead of print]. Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Expanded access programmes: patient interests versus clinical trial integrity. *Lancet Oncol.* 2015 Jan;16(1):15-7. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF_mutated melanoma. *N Engl J Med.* 2014; 371:1867-76. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka_Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalciou C, Chiarion_Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren_Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. *N Engl J Med.* 2014 Nov 16. [Epub ahead of print]. Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Expanded access programmes: patient interests versus clinical trial integrity. *Lancet Oncol.* 2015 Jan;16(1):15-7. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti_CTLA_4 treatment (CheckMate 037): a randomised, controlled, open_label, phase 3 trial. *Lancet Oncol.* 2015 Apr;16(4):375-84. Eggermont AM, Chiarion_Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A. Adjuvant ipilimumab versus placebo after complete resection of high_risk stage III melanoma (EORTC 18071): a randomised, double_blind, phase 3 trial. *Lancet Oncol.* 2015 May;16(5):522-30. Bassett_Sequin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licita L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre_planned interim analysis of an international, open_label trial. *Lancet Oncol.* 2015

Jun;16(6):729-36. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med*. 2015 Jul 2;373(1):23-34. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE_002): a randomised, controlled, phase 2 trial. *Lancet Oncol*. 2015 Aug;16(8):908-18. Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A, Cavalcanti E, Botti G, Mozzillo N, Ascierto PA, Marincola FM, Trivali S. RAN signaling in melanoma: implications for the development of alternative therapeutic strategies. *Cancer Lett*. 2015 Feb 1;357(1):286-96. Ascierto PA. Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma. *Cancer Immunol Immunother*. 2015 Mar;64(3):271-4. Manca A, Lissia A, Capone M, Ascierto PA, Botti G, Caracò C, Stanganelli I, Colombino M, Sini M, Cossu A, Palmieri G. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. *J Transl Med*. 2015 Jan 28;13:37. Peris K, Licitra L, Ascierto PA, Corvò R, Simonacci M, Picciotto F, Gualdi G, Pellacani G, Santoro. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. *Future Oncol*. 2015 Feb;11(4):703-12. Mozzillo N., Simeone E., Benedetto L., Curvietto M., Giannarelli, Gentilecore G, Camerlingo R., Capone M., Madonna M., Festino L., Caracò C., Di Monta G., Marone U., Di Marzo Massimiliano, Grimaldi A.M., Mori S., Ciliberto G. Ascierto P.A. Assessing a novel immuno-oncology based combination therapy: Ipilimumab plus electrochemotherapy. *Oncoimmunology* Published online. 22 May 2015. Di Trollo R, Di Lorenzo G, Fumo B, Ascierto PA. Cosmic radiation and cancer: is there a link? *Future Oncol*. 2015;11(7):1123-35. Romano S, D'Angelillo A, Staibano S, Simeone E, D'Arrigo P, Ascierto PA, Scalvenzi M, Mascolo M, Iardi G, Merolla F, Jovarauskaite E, Romano MF. Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients. *Pigment Cell Melanoma Res*. 2015 Jul;28(4):442-52. Del Vecchio M, Ascierto PA, Mandalà M, Sileni VC, Maio M, Di Guardo L, Simeone E, Queirolo P. Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. *Future Oncol*. 2015 May;11(9):1355-62. Calzavara Pinton P, Licitra L, Peris K, Santoro A, Ascierto PA. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. *Future Oncol*. 2015 May;11(9):1429-35. Basset-Seguín N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma (STEVE): a pre-planned interim analysis of an international, open-label trial. *Lancet Oncol*. 2015 Jun;16(6):729-36. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med*. 2015 May 31. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE_002): a randomised, controlled, phase 2 trial. *Lancet Oncol*. 2015 Jun 23. pii: S1470-2045(15)00083-2. Grimaldi AM, Simeone E, Palla M, Festino L, Caracò C, Mozzillo N, Petrillo A, Muto P, Ascierto PA. Vemurafenib beyond progression in a patient with metastatic melanoma: a case report. *Anticancer Drugs*. 2015 Apr;26(4):464-8. Fattore L, Malpicci D, Marra E, Belleudi F, Noto A, De Vitis C, Pisanu ME, Coluccia P, Camerlingo R, Roscilli G, Ribas A, Di Napoli A, Torrisi MR, Aurisicchio L, Ascierto PA, Mancini R, Ciliberto G. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. *Oncotarget*. 2015 Jul 7. Grimaldi AM, Simeone E, Festino L, Vanella V, Palla M, Ascierto PA. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. *Discov Med*. 2015 Jun;19(107):455-61. Ascierto PA, Marincola FM, Atkins MB. What's new in melanoma? Combination! *J Transl Med*. 2015 Jul 4;13:213. doi: 10.1186/s12967-015-0582-0. Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stronck D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. *J Transl Med*. 2015 Nov 30;13:374. Dummer R, Schadendorf D, Ascierto PA, Larkin J, Lebbé C, Hauschild A. Integrating first-line treatment options into clinical practice: what's new in advanced melanoma? *Melanoma Res*. 2015 Dec;25(6):461-9. Fusi A, Festino L, Botti G, Masucci G, Melero I, Lorigan P, Ascierto PA. PD-L1 expression as a potential predictive biomarker. *Lancet Oncol*. 2015 Oct;16(13):1285-7. De Divitiis C, von Arx C, Grimaldi AM, Cicala D, Tatangelo F, Arcella A, Romano GM, Simeone E, Iaffaioli RV, Ascierto PA, Tafuto S; Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. *European Neuroendocrine Tumor Society (ENETS) Center of Excellence. Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy)* *J Transl Med*. 2016 May 3;14(1):113. doi: 10.1186/s12967-016-0857-1. Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, Melero I, Ascierto PA. Drugs. *Cancer Treatment with Anti-PD-L1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?* 2016 Jun;76(9):925-45. doi: 10.1007/s40265-016-0588-x. Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. *Eur J Cancer*. 2016 Jan;53:125-34. doi: 10.1016/j.ejca.2015.09.013. Epub 2015 Dec 17. Casula M, Colombino M, Manca A, Caracò C, Botti G, Ascierto PA, Lissia A, Cossu A, Palmieri G; Italian Melanoma Intergroup (IMI). Low levels of genetic heterogeneity in matched lymph node metastases from melanoma patients. *J Invest Dermatol*. 2016 Jun 2. pii: S0022-202X(16)31332-X. doi: 10.1016/j.jid.2016.05.103. [Epub ahead of print] PubMed PMID: 27265006. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol*. 2016 Jun 3. pii: S1470-2045(16)30098-5. doi: 10.1016/S1470-2045(16)30098-5. [Epub ahead of print] PubMed PMID: 27269741. Ascierto PA, Long GV. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. *Lancet Oncol*. 2016 Jun 17. pii: S1470-2045(16)30017-1. doi: 10.1016/S1470-2045(16)30017-1. [Epub ahead of print] PubMed PMID: 27324281. Hoeller C, Michielin O, Ascierto PA, Szabo Z, Blank CU. Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. *Cancer Immunol Immunother*. 2016 Jul 2. [Epub ahead of print] Review. PubMed PMID: 27372293. Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Demuth I, Steinhagen-Thiessen E, Larbi A, Schilling B, Schadendorf D, Wolchok JD, Blank CU, Pawelec G, Garbe C, Weide B. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. *Eur J Cancer*. 2016 Jul 8;64:116-126. doi: 10.1016/j.ejca.2016.06.001. [Epub ahead of print] PubMed PMID: 27400322. Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I, Dastani HB, Waxman IM, Abernethy AP. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase 3 checkmate 066 study. *Ann Oncol*. 2016 Jul 12. pii: mdw265. [Epub ahead of print] PubMed PMID: 27405322. Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, Fontana V, Giorrello L, Merlo DF, Simeone E, Grimaldi AM, Curvietto M, Del Vecchio M, Bruzzi P, Ascierto PA. Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib. *Oncotarget*. 2016 Jul 13. doi: 10.18632/oncotarget.10589. [Epub ahead of print] PubMed PMID: 27418142. Campana LG, Testori A, Curatolo P, Quagliano P, Mocellin S, Framarini M, Borgognoni L, Ascierto PA, Mozzillo N, Guida M, Bucher S, Rotunno R, Marengo F, De Salvo GL, De Paoli A, Rossi CR, Bonadies A. Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. *Eur J Surg Oncol*. 2016 Jun 29. pii: S0748-7983(16)30600-0. doi: 10.1016/j.ejso.2016.06.399. [Epub ahead of print] PubMed PMID: 27424789. Strizzi L, Margaryan NV, Gerami P,

Haghighat Z, Harms PW, Madonna G, Botti G, Ascierto PA, Hendrix MJ. Translational significance of Nodal, Cripto_1 and Notch4 in adult nevi. *Oncol Lett*. 2016 Aug;12(2):1349_1354. Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liskay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz_Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J. Cobimetinib combined with vemurafenib in advanced BRAF(V600)_mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2016 Jul 29. pii: S1470_2045(16)30122_X. doi:10.1016/S1470_2045(16)30122_X. Saia P, Gutzmer R, Ascierto PA, Maio M, Grob JJ, Muraw P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Vojtek I, Peeters O, Brichard VG, Therasse P. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE_A3 immunotherapeutic (PREDICT). *Ann Oncol*. 2016 Aug 8. pii: mdw291. [Epub ahead of print] PubMed PMID: 27502712. Fattore L, Mancini R, Acunzo M, Romano G, Laganà A, Pisanu ME, Malpicci D, Madonna G, Mallardo D, Capone M, Fulciniti F, Mazzucchelli L, Botti G, Croce CM, Ascierto PA, Ciliberto G. miR_579_3p controls melanoma progression and resistance to target therapy. *Proc Natl Acad Sci U S A*. 2016 Aug 8. pii: 201607753. [Epub ahead of print] PubMed PMID: 27503895. Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. *Oncologist*. 2016 Aug 10. pii: theoncologist.2016_0186. [Epub ahead of print] PubMed PMID: 27511905. Ascierto PA, Vanella V, Grimaldi AM, Lucia F, Palla M, Simeone E, Mozzillo N. Complete response to nivolumab monotherapy in a treatment-naïve, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. *Cancer Immunol Immunother*. 2016 Sep 7. [Epub ahead of print] PubMed PMID: 27604993. Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, Capone M. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. *J Transl Med*. 2016 Sep 20;14(1):273. PubMed PMID: 27650038. Gridelli C, Ascierto PA, Barberis MC, Felip E, Garon EB, O'Brien M, Senan S, Casaluce F, Sgambato A, Papadimitrakopoulou V, De Marinis F. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. *Expert Opin Biol Ther*. 2016 Sep 21:1_11. [Epub ahead of print] PubMed PMID: 27650132. Carlino MS, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L, Kefford RF, Menzies AM, Long GV, Ascierto PA. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. *Br J Cancer*. 2016 Oct 6. doi: 10.1038/bjc.2016.321. PubMed PMID: 27711085. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. *N Engl J Med*. 2016 Oct 7. PubMed PMID: 27717298. Botticelli A, Zizzari I, Mazza F, Ascierto PA, Putignani L, Marchetti L, Napolitano C, Nuti M, Marchetti P. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. *Oncotarget*. 2016 Oct 28. doi: 10.18632/oncotarget.12985. [Epub ahead of print] Review. PubMed PMID: 27806346. Gutzmer R, Rivoltini L, Levchenko E, Testori A, Utikal J, Ascierto PA, Demidov L, Grob JJ, Ridolfi R, Schadendorf D, Queirolo R, Santoro A, Loquai C, Dreno B, Hauschild A, Schultz E, Lesimple TP, Vanhoutte N, Salaun B, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF. Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. *ESMO Open*. 2016 Aug 8;1(4):e000068. PubMed PMID:27843625; PubMed Central PMCID: PMC5070281. Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto PA, Rekers N, Straten PT, Awada A. Cancer immunotherapy: from the lab to clinical applications. Potential impact on cancer centres' organisation. *Ecanermediscience*. 2016 Nov 10;10:691. PubMed PMID: 27994647; PubMed Central PMCID: PMC5130327. Simeone E, Grimaldi AM, Festino L, Vanella V, Palla M, Ascierto PA. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. *BioDrugs*. 2017 Feb;31(1):51_61. doi: 10.1007/s40259_016_0208_z. Review. PubMed PMID: 28058658. Cantile M, Scognamiglio G, Marra L, Aquino G, Botti C, Falcone MR, Malzone MG, Liguori G, Di Bonito M, Franco R, Ascierto PA, Botti G. HOTAIR Role in Melanoma Progression and its Identification in the Blood of Patients with Advanced Disease. *J Cell Physiol*. 2017 Jan 9. doi: 10.1002/jcp.25789. [Epub ahead of print] PubMed PMID: 28067428. Palmieri G, Colombino M, Cossu A, Marchetti A, Botti G, Ascierto PA. Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? *J Transl Med*. 2017 Jan 21;15(1):17. doi:10.1186/s12967_017_1119_6. PubMed PMID: 28109293; PubMed Central PMCID: PMC5251272. Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, Mancini R, Ciliberto G. MicroRNAs in melanoma development and resistance to target therapy. *Oncotarget*. 2017 Jan 19. doi: 10.18632/oncotarget.14763. [Epub ahead of print] Review. PubMed PMID: 28118616. Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bottomley A, Kotapati S, de Pril V, Testori A, Eggermont AM. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2017 Feb 2. pii: S1470_2045(17)30015_3. doi:10.1016/S1470_2045(17)30015_3. [Epub ahead of print] PubMed PMID: 28162999. Wistuba-Hamprecht K, Martens A, Heubach F, Romano E, Geukes-Foppen M, Yuan J, Postow M, Wong P, Mallardo D, Schilling B, Di Giacomo AM, Khammari A, Dreno B, Maio M, Schadendorf D, Ascierto PA, Wolchok JD, Blank CU, Garbe C, Pawelec G, Weide B. Peripheral CD8 effector memory type 1 T cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. *Eur J Cancer*. 2017 Feb 3;73:61_70. doi: 10.1016/j.ejca.2016.12.011. [Epub ahead of print] PubMed PMID: 28167454. Itchins M, Ascierto PA, Menzies AM, Oatley M, Lo S, Douraghi-Zadeh D, Harrington T, Maher R, Grimaldi AM, Guminski A. A multiferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. *Melanoma Res*. 2017 Feb 22. doi: 10.1097/CMR.0000000000000343. [Epub ahead of print] PubMed PMID: 28230715. Botti G, Fratangelo F, Cerrone M, Liguori G, Cantile M, Anniciello AM, Scala S, D'Alterio C, Trimarco C, Ianaro A, Cirino G, Caracò C, Colombino M, Palmieri G, Pepe S, Ascierto PA, Sabbatino F, Scognamiglio G. COX_2 expression positively correlates with PD-L1 expression in human melanoma cells. *J Transl Med*. 2017 Feb 23;15(1):46. doi: 10.1186/s12967_017_1150_7. PubMed PMID: 28231855. Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandalà M, Thomas L, Demidov L, Garbe C, Hogg D, Liskay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2017 Apr;18(4):435_445. doi:10.1016/S1470_2045(17)30180_8. Epub 2017 Mar 9. PubMed PMID: 28284557. Zito Marino F, Ascierto PA, Rossi G, Staibano S, Montella M, Russo D, Alfano R, Morabito A, Botti G, Franco R. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? *Expert Opin Biol Ther*. 2017 Jun;17(6):735_746. doi: 10.1080/14712598.2017.1309387. Epub 2017 Mar 28. PubMed PMID: 28318336. Ascierto PA, Accorona R, Botti G, Farina D, Fossati P, Gatta G, Gogas H, Lombardi D, Maroldi R, Nicolai P, Ravanelli M, Vanella V. Mucosal melanoma of the head and neck. *Crit Rev Oncol Hematol*. 2017 Apr;112:136_152. doi:10.1016/j.critrevonc.2017.01.019. Epub 2017 Feb 13. Review. PubMed PMID:28325255. Talerico R, Cristiani CM, Staaf E, Garofalo C, Sottile R, Capone M, Pico de Coaña Y, Madonna G, Palella E, Wolodarski M, Carannante V, Mallardo D, Simeone E, Grimaldi AM, Johansson S, Frumento P, Gulletta E, Anichini A, Colucci F, Ciliberto G, Kiessling R, Kärre K, Ascierto PA, Carbone E. IL_15, TIM_3 and NK cells subsets predict responsiveness to anti-CTLA_4 treatment in melanoma patients. *Oncoimmunology*. 2016 Dec 7;6(2):e1261242. doi:10.1080/2162402X.2016.1261242. eCollection 2017. PubMed PMID: 28344869; PubMed Central PMCID: PMC5353942. Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liskay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol*. 2017 May;18(5):611_622. doi:10.1016/S1470_2045(17)30231_0. Epub 2017 Mar 27. PubMed PMID: 28359784. Simeone E, Grimaldi AM, Festino L, Giannarelli D, Vanella V, Palla M, Curvietto M, Esposito A, Palmieri G, Mozzillo N, Ascierto PA. Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. *Oncoimmunology*. 2017 Jan 19;6(3):e1283462. doi: 10.1080/2162402X.2017.1283462. eCollection 2017. PubMed PMID: 28405510; PubMed Central PMCID: PMC5384373. Helgadottir H, Kis L, Ljungman P, Larkin J,

Kefford R, Ascierto PA, Hansson J, Masucci G. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. *Ann Oncol*. 2017 Apr 12. doi: 10.1093/annonc/mdx177. [Epub ahead of print] PubMed PMID: 28407116. Romano S, Simeone E, D'Angelillo A, D'Arrigo P, Russo M, Capasso M, Lasorsa VA, Zambrano N, Ascierto PA, Romano MF. FKBPS1s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy. *Cancer Immunol Immunother*. 2017 Apr 22. doi:10.1007/s00262_017_1186_8. [Epub ahead of print] PubMed PMID: 28434031. Di Monta G, Caracò C, Simeone E, Grimaldi AM, Marone U, Di Marzo M, Vanella V, Festino L, Palla M, Mori S, Mozzillo N, Ascierto PA. Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22_cases retrospective analysis. *J Transl Med*. 2017 Apr 26;15(1):82. doi: 10.1186/s12967_017_1186_8. PubMed PMID: 28441954; PubMed Central PMCID: PMC5405498. Dréno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, Grob JJ, Koralek DO, Rooney I, Hsu JJ, McKenna EF, McArthur GA. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. *Ann Oncol*. 2017 May 1;28(5):1137_1144. doi:10.1093/annonc/mdx040. PubMed PMID: 28444112. Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglini P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP. Association of CTLA_4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. *Front Immunol*. 2017 Apr 12;8:386. doi: 10.3389/fimmu.2017.00386. eCollection 2017. PubMed PMID: 28446908; PubMed Central PMCID: PMC5388686. Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP. Open_label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation_positive metastatic melanoma: 2_year follow-up data and long-term responders' analysis. *Eur J Cancer*. 2017 Jul;79:176_184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11. PubMed PMID: 28501764. McArthur GA, Mohr P, Ascierto PA, Arance A, Banos Hernandez A, Kaskel P, Weichenthal M, Shinde R, Stevinson K. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITON Study). *Oncologist*. 2017 May 19. pii:theoncologist.2016_0272. doi: 10.1634/theoncologist.2016_0272. [Epub ahead of print] PubMed PMID: 28526721. Wongchenko MJ, McArthur GA, Dréno B, Larkin J, Ascierto PA, Sosman J, Andries L, Kockx M, Hurst SD, Caro I, Rooney I, Hegde PS, Molinero L, Yue H, Chang I, Amler LC, Yan Y, Ribas A. Gene Expression Profiling in BRAF_Mutated Melanoma Reveals Patient Subgroups With Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. *Clin Cancer Res*. 2017 May 23. pii:clincanres.0172.2017. doi: 10.1158/1078_0432.CCR_17_0172. [Epub ahead of print] PubMed PMID: 28536307. Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M, Ascierto PA. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. *Am J Clin Dermatol*. 2017 May 23. doi: 10.1007/s40257_017_0292_y. [Epub ahead of print] Review. PubMed PMID: 28537004. Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM, Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi_institutional retrospective study. *Eur J Cancer*. 2018 Mar;91:116_124. doi: 10.1016/j.ejca.2017.12.007. Ascierto PA, Eggermont AMM. Neoadjuvant therapy in melanoma: the next step? *Lancet Oncol*. 2018 Feb;19(2):151_153. doi: 10.1016/S1470_2045(18)30016_0. Epub 2018 Jan 18. PubMed PMID: 29361473. Weber J, Qureshi A, Ascierto PA. Adjuvant Therapy in Resected Melanoma. *N Engl J Med*. 2018 Feb 15;378(7):680. doi: 10.1056/NEJMc1716071. PubMed PMID: 29446288. Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators. Adjuvant vemurafenib in resected, BRAF(V600) mutation_positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Oncol*. 2018 Apr;19(4):510_520. doi: 10.1016/S1470_2045(18)30106_2. Epub 2018 Feb 21. Erratum in: *Lancet Oncol*. 2018 Apr;19(4):e184. PubMed PMID: 29477665. Soldati L, Di Renzo L, Jirillo E, Ascierto PA, Marincola FM, De Lorenzo A. The influence of diet on anti_cancer immune responsiveness. *J Transl Med*. 2018 Mar 20;16(1):75. doi: 10.1186/s12967_018_1448_0. Review. PubMed PMID: 29558948; PubMed Central PMCID: PMC5859494. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandalà M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion_Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh_de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF_mutant melanoma (COLUMBUS): a multicentre, open_label, randomised phase 3 trial. *Lancet Oncol*. 2018 Mar 21. pii: S1470_2045(18)30142_6. doi: 10.1016/S1470_2045(18)30142_6. [Epub ahead of print] PubMed PMID: 29573941. Capone I, Marchetti P, Ascierto PA, Malorni W, Gabriele L. Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. *Front Immunol*. 2018 Mar 21;9:552. doi: 10.3389/fimmu.2018.00552. eCollection 2018. PubMed PMID: 29619026; PubMed Central PMCID: PMC5871673. Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez_Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *N Engl J Med*. 2018 Apr 15. doi: 10.1056/NEJMoa1802357. [Epub ahead of print] PubMed PMID: 29658430. Ascierto PA, Caracò C, Gershenwald JE, Hamid O, Ross M, Sullivan RJ, Puzanov I. The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. *J Transl Med*. 2018 Apr 17;16(1):101. doi: 10.1186/s12967_018_1477_8. PubMed PMID: 29665799. Audrito V, Managò A, Zamporlini F, Rulli E, Gaudino F, Madonna G, D'Atri S, Antonini Cappellini GC, Ascierto PA, Massi D, Raffaelli N, Mandalà M, Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF_mutated metastatic melanoma. *Oncotarget*. 2018 Apr 10;9(27):18997_19005. doi: 10.18632/oncotarget.24871. eCollection 2018 Apr 10. PubMed PMID: 29721178; PubMed Central PMCID: PMC5922372. Cavalieri S, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P. Efficacy and safety of single_agent pan_human epidermal growth factor receptor (HER) inhibitor dacotinib in locally advanced unresectable or metastatic skin squamous cell cancer. *Eur J Cancer*. 2018 May 4;97:7_15. doi: 10.1016/j.ejca.2018.04.004. [Epub ahead of print] PubMed PMID: 29734047. Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small_Cell Lung Cancer. *Cancer Cell*. 2018 Apr 21. pii: S1535_6108(18)30172_7. doi: 10.1016/j.ccell.2018.04.001. [Epub ahead of print] PubMed PMID: 29731394. Queirolo P, Dozin B, Morabito A, Banelli B, Carosio R, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Ascierto PA, Madonna G, Simeone E, De Galitiis F, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Ghilardi L, Merelli B, Fava P, Osella_Abate S, Guidoboni M, Romani M, Ferone D, Spagnolo F, Pistillo MP; Italian Melanoma Intergroup (IMI). CTLA_4 gene variant _1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. *Eur J Cancer*. 2018 May 7. pii: S0959_8049(18)30787_1. doi:10.1016/j.ejca.2018.04.005. [Epub ahead of print] PubMed PMID: 29743138. Ascierto PA, Bastholt L, Ferrucci PF, Hansson J, Márquez Rodas I, Payne M, Robert C, Thomas L, Utikal JS, Wolter P, Kudlac A, Tuson H, McKendrick J. The impact of patient characteristics and disease_specific factors on first_line treatment decisions for BRAF_mutated melanoma: results from a European expert panel study. *Melanoma Res*. 2018 May 10. doi: 10.1097/CMR.0000000000000455. [Epub ahead of print] PubMed PMID: 29750751. Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink_Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret_Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi_Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzella L, Konopasek B, Dunder P, Skaloova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros_Merino C, Dijkstra J, van de Water C, van Lent_van Vliet S, Knijn N, Muşină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhashi T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J. International validation of

the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet*. 2018 May 10. pii: S0140_6736(18)30789_X. doi: 10.1016/S0140_6736(18)30789_X. [Epub ahead of print] PubMed PMID: 29754777. Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29_30 November, 2017, Naples, Italy). *J Immunother Cancer*. 2018 Jul 11;6(1):69. doi: 10.1186/s40425_018_0377_z. Review. PubMed PMID: 29996914; PubMed Central PMCID: PMC6042369. Fratangelo F, Camerlingo R, Carriero MV, Pirozzi G, Palmieri G, Gentile G, Ragone C, Minopoli M, Ascierto PA, Motti ML. Effect of ABT_888 on the apoptosis, motility and invasiveness of BRAF_i-resistant melanoma cells. *Int J Oncol*. 2018 Sep;53(3):1149_1159. doi: 10.3892/ijo.2018.4457. Epub 2018 Jun 27. PubMed PMID: 29956724; PubMed Central PMCID: PMC6065454. Gridelli C, Ascierto PA, Grossi F, Baldini E, Favaretto A, Garassino MC, Morabito A, Miglino MR, Rossi A, de Marinis F. Second_line treatment of advanced non_small cell lung cancer non_oncogene addicted: new treatment algorithm in the era of novel immunotherapy. *Curr Clin Pharmacol*. 2018 Jul 11. doi: 10.2174/1574884713666180711160008. [Epub ahead of print] PubMed PMID: 29992894. Sommariva A, Forsea AM, Agius D, Ascierto PA, Bastiaannet E, Borgognoni L, Demetriou A, Garbe C, Gavric Z, Hocevar M, Innos K, Larønningsen S, Louwman M, Robsahm TE, Rutkowski P, van Akkooi A, Zorzi M, Pasquali S, van de Velde C, Rossi CR. Quality assurance in melanoma care: The EU_MELACARE study. *Eur J Surg Oncol*. 2018 Jul 3. pii: S0748_7983(18)31164_8. doi: 10.1016/j.ejso.2018.06.020. [Epub ahead of print] PubMed PMID: 30001892. Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA. Baseline neutrophil_to_lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. *J Immunother Cancer*. 2018 Jul 16;6(1):74. doi: 10.1186/s40425_018_0383_1. PubMed PMID: 30012216; PubMed Central PMCID: PMC6048712. Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehner JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November_2 December, 2017, Naples, Italy). *J Transl Med*. 2018 Jul 21;16(1):207. doi: 10.1186/s12967_018_1568_6. PubMed PMID: 30031393; PubMed Central PMCID: PMC6054754. Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600_Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. *JAMA Oncol*. 2018 Aug 2. doi: 10.1001/jamaoncol.2018.2668. [Epub ahead of print] PubMed PMID: 30073321. Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaike M, Le DT. CheckMate_032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. *J Clin Oncol*. 2018 Aug 15;JCO2017766212. doi: 10.1200/JCO.2017.76.6212. [Epub ahead of print] PubMed PMID: 30110194. Salemi R, Falzone L, Madonna G, Polesel J, Cinà D, Mallardo D, Ascierto PA, Libra M, Candido S. MMP_9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating_Free DNA. *Front Pharmacol*. 2018 Aug 14;9:856. doi: 10.3389/fphar.2018.00856. eCollection 2018. PubMed PMID: 30154717; PubMed Central PMCID: PMC6102751. Festino L, Vanella V, Trojaniello C, Ascierto PA. Selecting immuno_oncology_based drug combinations _ what should we be considering? *Expert Rev Clin Pharmacol*. 2018 Sep 8;1_15. doi: 10.1080/17512433.2018.1518713. [Epub ahead of print] PubMed PMID: 30169990. Simeone E, Ascierto PA. Anti_PD_1 and PD_L1 antibodies in metastatic melanoma. *Melanoma Manag*. 2017 Dec;4(4):175_178. doi: 10.2217/mmt_2017_0018. Epub 2017 Nov 21. PubMed PMID: 30190923; PubMed Central PMCID: PMC6094668. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh_de Parseval LA, Pickard MD, Sander V, Robert C, Flaherty KT. Overall survival in patients with BRAF_mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open_label, randomised, phase 3 trial. *Lancet Oncol*. 2018 Sep 12. pii: S1470_2045(18)30497_2. doi: 10.1016/S1470_2045(18)30497_2. [Epub ahead of print] PubMed PMID: 30219628. Ascierto PA, Dummer R. Immunological effects of BRAF+MEK inhibition. *Oncoimmunology*. 2018 Jul 23;7(9):e1468955. doi: 10.1080/2162402X.2018.1468955. eCollection 2018. Review. PubMed PMID: 30228935; PubMed Central PMCID: PMC6140547. Fattore L, Ruggiero CF, Pisanu ME, Liguoro D, Cerri A, Costantini S, Capone F, Acunzo M, Romano G, Nigita G, Mallardo D, Ragone C, Carriero MV, Budillon A, Botti G, Ascierto PA, Mancini R, Ciliberto G. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. *Cell Death Differ*. 2018 Sep 25. doi: 10.1038/s41418_018_0205_5. [Epub ahead of print] PubMed PMID: 30254376. Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahmian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhring K, Massaccesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J. Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT_IT). *Ann Oncol*. 2018 Oct 8. doi: 10.1093/annonc/mdy423. [Epub ahead of print] PubMed PMID: 30295695. Ascierto PA, Marabelle A. How do immune checkpoint targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies. *Ann Oncol*. 2018 Oct 11. doi: 10.1093/annonc/mdy420. [Epub ahead of print] PubMed PMID: 30307539. Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Coccorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglini P, Fava P, Osella_Abate S, Ascierto PA, Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P; Italian Melanoma Intergroup (IMI). Soluble CTLA_4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. *Cancer Immunol Immunother*. 2018 Oct 11. doi: 10.1007/s00262_018_2258_1. [Epub ahead of print] PubMed PMID: 30311027. Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM. Anti_PD_1/PD_L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. *Eur J Cancer*. 2018 Oct 19;104:137_144. doi: 10.1016/j.ejca.2018.09.017. [Epub ahead of print] PubMed PMID: 30347289. Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka_Warchocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalciou C, Chiarion Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Sazi A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients With Previously Untreated BRAF Wild_Type Advanced Melanoma Treated With Nivolumab Therapy: Three_Year Follow_up of a Randomized Phase 3 Trial. *JAMA Oncol*. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514. [Epub ahead of print] PubMed PMID: 30422243. Fattore L, Mancini R, Ascierto PA, Ciliberto G. The potential of BRAF associated non_coding RNA as a therapeutic target in melanoma. *Expert Opin Ther Targets*. 2018 Dec 3. doi: 10.1080/14728222.2019.1554057. [Epub ahead of print] PubMed PMID: 30507327. Grob JJ, Garbe C, Ascierto P, Larkin J, Dummer R, Schadendorf D. Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? *Lancet Oncol*. 2018 Dec;19(12):e720_e725. doi: 10.1016/S1470_2045(18)30596_5. Review. PubMed PMID: 30507438. Madonna G, Ballesteros_Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caracò C, Botti G, Fox BA, Ascierto PA. PD_L1 expression with immune_infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. *Oncoimmunology*. 2018 Sep 5;7(12):e1405206. doi: 10.1080/2162402X.2017.1405206. eCollection 2018. PubMed PMID: 30524879; PubMed Central PMCID: PMC6279420. Pisanu ME, Mauerer_Saccà M, Fattore L, Bruschini S, De Vitis C, Tabbi E, Bellei B, Migliano E, Kovacs D, Camera E, Picardo M, Jakopin Z, Cipitelli C, Bartolazzi A, Raffa S, Torrisi MR, Fulcinitti F, Ascierto PA, Ciliberto G, Mancini R. Inhibition of Stearoyl_CoA desaturase 1 reverts BRAF and MEK inhibition induced selection of cancer stem cells in BRAF_mutated melanoma. *J Exp Clin Cancer Res*. 2018 Dec 17;37(1):318. doi: 10.1186/s13046_018_0989_7. PubMed PMID: 30558661; PubMed Central PMCID: PMC6298024. Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C. An open_label, multicentre safety study of vemurafenib in patients with BRAF(V600)_mutant metastatic melanoma: final analysis and a validated prognostic scoring system. *Eur J Cancer*. 2018 Dec 20;107:175_185. doi: 10.1016/j.ejca.2018.11.018. [Epub ahead of print] PubMed PMID: 30580112. Cristiani CM, Turdo A, Ventura V, Apuzzo T, Capone M, Madonna G, Mallardo D, Garofalo C, Giovannone ED, Grimaldi AM, Talerico R, Marcenaro E, Pesce S, Zotto GD, Agosti V, Costanzo FS, Gulletta E, Rizzo A, Moretta A, Karre K, Ascierto PA, Todaro M, Carbone E. Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution

and Reveals a CCL19-Dependent Metastatic Pathway. *Cancer Immunol Res.* 2019 Apr 2. doi: 10.1158/2326_6066.CIR_18_0651. [Epub ahead of print] PMID: 30940644 Ascierto PA, Capone M, Grimaldi AM, Mallardo D, Simeone E, Madonna G, Roder H, Meyer K, Asmellash S, Oliveira C, Roder J, Grigorieva J. Proteomic test for anti_PD_1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. *J Immunother Cancer.* 2019 Mar 29;7(1):91. doi: 10.1186/s40425_019_0569_1. PMID: 30925943 Free PMC Article

Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebke C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A. Adverse events 2.0. Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immuno-oncology. *Eur J Cancer.* 2019 Mar 21;112:29_31. doi: 10.1016/j.ejca.2019.01.015. [Epub ahead of print] No abstract available. PMID: 30903870 Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A. Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600E-mutated Metastatic Melanoma. *Clin Cancer Res.* 2019 Mar 1. doi: 10.1158/1078_0432.CCR_18_0720. [Epub ahead of print] PMID: 30824584 Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIb/IV CheckMate 511 Trial. *J Clin Oncol.* 2019 Apr 10;37(11):867_875. doi: 10.1200/JCO.18.01998. Epub 2019 Feb 27. PMID: 30811280 Schilling B, Martens A, Geukes-Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B. First-line therapy: stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. *Cancer Immunol Immunother.* 2019 May;68(5):765_772. doi: 10.1007/s00262_019_02311_1. Epub 2019 Feb 26. PMID: 30806748 Pascarella G, Capasso A, Nardone A, Triassi M, Pignata S, Arenare L, Ascierto P, Curvietto M, Maiolino P, D'Aniello R, Montanino A, Laudato F, De Feo G, Botti G, Perrone F, Petrillo A, Cavalcanti E, Lastoria S, Maurea N, Morabito A. Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology. *PLoS One.* 2019 Jan 8;14(1):e0210330. doi: 10.1371/journal.pone.0210330. eCollection 2019. PMID: 30620767 Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalá M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutski M, Blank C. An open-label, multicentre safety study of vemurafenib in patients with BRAFV600E-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. *Eur J Cancer.* 2019 Jan;107:175_185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE_158 Study. *J Clin Oncol.* 2020 Jan 1;38(1):1_10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4. PMID: 31682550. Eggermont AMM, Kicinski M, Blank CU, Mandalá M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suci S. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol.* 2020 Jan 2. doi:10.1001/jamaoncol.2019.5570. [Epub ahead of print] PubMed PMID: 31895407. Luke JJ, Ascierto PA. Biology confirmed but biomarkers elusive in melanoma immunotherapy. *Nat Rev Clin Oncol.* 2020 Jan 23. doi: 10.1038/s41571_020_0328_8. [Epub ahead of print] PubMed PMID: 31974501. Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrer G, Tsai KK, van Akkooi A, Funchain P. Systemic Therapy for Melanoma: ASCO Guideline. *J Clin Oncol.* 2020 Mar 31;JCO2000198. doi: 10.1200/JCO.20.00198. [Epub ahead of print] PubMed PMID: 32228358. Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, Butler MO, Delord JP, Gelderblom H, Ascierto PA, Fasolo A, Führer D, Hütter-Krönke ML, Forde PM, Wrona A, Santoro A, Sadow PM, Szpakowski S, Wu H, Bostel G, Faris J, Cameron S, Varga A, Taylor M. PD-1 Blockade in Anaplastic Thyroid Carcinoma. *J Clin Oncol.* 2020 May 4;JCO1902727. doi: 10.1200/JCO.19.02727. [Epub ahead of print] PubMed PMID: 32364844. Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, Yan Y, Huang KC, Uyei A, McNally V, McArthur GA, Ascierto PA. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600E mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2020;395(10240):1835_1844. doi:10.1016/S0140_6736(20)30934_X Eggermont AMM, Blank CU, Mandalá M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suci S, Robert C. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325_MG/KEYNOTE_054 Trial. *J Clin Oncol.* 2020 Sep 18;JCO2002110. doi: 10.1200/JCO.20.02110. Epub ahead of print. PMID: 32946353. Ascierto PA, Del Vecchio M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V, Loffredo J, Larkin J, Weber J. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. *Lancet Oncol.* 2020 Sep 18;S1470_2045(20)30494_0. doi: 10.1016/S1470_2045(20)30494_0. Epub ahead of print. PMID: 32961119. Ascierto PA, Marincola FM, Fox BA, Galon J. No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study. *Oncoimmunology.* 2020 Oct 13;9(1):1826132. doi: 10.1080/2162402X.2020.1826132. PMID: 33194317; PMCID: PMC7644246.

Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Fiorella C, Pinato DJ, **Ascierto PA**, Cortellini A. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. *Eur J Cancer.* 2020 Nov 16;142:18-28. doi: 10.1016/j.ejca.2020.09.033. Epub ahead of print. PMID: 33212418.

Marchetti P, Botticelli A, **Ascierto AP**, Curigliano G, Giannarelli D. Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. *J Transl Med.* 2020 Nov 25;18(1):446. doi: 10.1186/s12967-020-02588-2. PMID: 33239030; PMCID: PMC7688006.

Faries MB, **Ascierto PA**, Blank C, Cochran AJ, Delman K, Gyorki D, Haanen J, Hamid O, Han D, Karakousis G, Kashani-Sabet M, Leachman S, Moncrieff M, Plasmeljer E, Enrico Testori AA, Van Akkooi A, Wong S, Zager JS. Letter Regarding Editorial by Samuel Zagarella. *Am J Dermatopathol.* 2020 Dec 1. doi: 10.1097/DAD.0000000000001857. Epub ahead of print. PMID: 33264129.

Miscio L, Olivieri A, Labonia F, De Feo G, Chiodini P, Portella G, Atripaldi L, Parrella R, Conenna R, Buonaguro FM, Cavalcanti E, **Ascierto P**, Botti G, Bianchi A. Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection. *J Transl Med.* 2020 Dec 21;18(1):488. doi: 10.1186/s12967-020-02651-y. PMID: 33349261.

Scarpa R, Caso F, Costa L, Passavanti S, Vitale MG, Trojaniello C, Del Puente A, **Ascierto PA**. May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)? *J Transl Med.* 2020 Dec 22;18(1):489. doi: 10.1186/s12967-020-02673-6. PMID: 33353549.

Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens R, Svane IM, Lotem M, Abu-Amna M, Gasal E, Ghori R, Diede SJ, Croydon ES, Ribas A, **Ascierto PA**; KEYNOTE-022 international team. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. *J Immunother Cancer*. 2020 Dec;8(2):e001806. doi: 10.1136/jitc-2020-001806. PMID: 33361337.

Turiello R, Capone M, Giannarelli D, Morretta E, Monti MC, Madonna G, Mallardo D, Festino L, Azzaro R, Levesque MP, Imhof L, Weide B, Amaral T, Chevrier M, Sucker A, Rutkowski P, Schadendorf D, Lebke C, Luke JJ, Wistuba-Hamprecht K, Dummer R, Pinto A, Morello S, **Ascierto PA**. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. *J Immunother Cancer*. 2020 Dec;8(2):e001689. doi: 10.1136/jitc-2020-001689. PMID: 33361405.

Cozzolino M, Cocco S, Piezzo M, Celia G, Costantini S, Abate V, Capone F, Barberio D, Girelli L, Cavicchiolo E, **Ascierto PA**, Madonna G, Budillon A, De Laurentiis M. A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results. *J Clin Med*. 2021 Jan 3;10(1):E136. doi: 10.3390/jcm10010136. PMID: 33401546.

Trojaniello C, Vitale MG, **Ascierto PA**. Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better? *Curr Opin Oncol*. 2021 Jan 4; Publish Ahead of Print. doi: 10.1097/CCO.0000000000000709. Epub ahead of print. PMID: 33399314.

Vecchiato A, Mocellin S, Del Fiore P, Tosti G, **Ascierto PA**, Corradin MT, De Giorgi V, Giudice G, Queirolo P, Ferrelli C, Occelli M, Giordano M, Trevisan G, Mascheroni L, Testori A, Spina R, Buja A, Cavallin F, Caracò C, Sommariva A, Rossi CR; Clinical National Melanoma Registry Study Group at the Italian Melanoma Intergroup (IMI). The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates. *BMC Cancer*. 2021 Jan 5;21(1):8. doi: 10.1186/s12885-020-07705-4. PMID: 33402122.

Simeone E, Scognamiglio G, Capone M, Giannarelli D, Grimaldi AM, Mallardo D, Madonna G, Curvietto M, Esposito A, Sandomenico F, Sabbatino F, Bayless NL, Warren S, Ong S, Botti G, Flaherty KT, Ferrone S, **Ascierto PA**. A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. *J Transl Med*. 2021 Jan 6;19(1):17. doi: 10.1186/s12967-020-02680-7. PMID: 33407577.

Ascierto PA, Butterfield LH, Campbell K, Daniele B, Dougan M, Emens LA, Formenti S, Janku F, Khleif SN, Kirchhoff T, Morabito A, Najjar Y, Nathan P, Odunsi K, Patnaik A, Paulos CM, Reinfeld BI, Skinner HD, Timmerman J, Puzanov I. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). *J Transl Med*. 2021 Jan 6;19(1):13. doi: 10.1186/s12967-020-02627-y. PMID: 33407605.

Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupo J, Vaisman A, Saibil SD, Butler MQ, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, **Ascierto PA**, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. *J Immunother Cancer*. 2021 Jan;9(1):e001931. doi: 10.1136/jitc-2020-001931. PMID: 33468556.

Guida A, Perri F, Ionna F, **Ascierto PA**, Grimaldi AM. New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy. *Clin Case Rep*. 2020 Dec 2;9(1):61-66. doi: 10.1002/ccr3.3418. PMID: 33489133; PMCID: PMC7813008.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, **Ascierto PA**, Rutkowski P, Schadendorf D, Koonstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreard S, Kicinski M, Suci S, Robert C. Reply to E. Hindie. *J Clin Oncol*. 2021 Jan 25;JCO2003463. doi: 10.1200/JCO.20.03463. Epub ahead of print. PMID: 33492998.

Guida M, Bartolomeo N, Quagliano P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, Ridolfi L, Queirolo P, De Risi I, Quaresmini D, Gambale E, Chiaron Sileni V, **Ascierto PA**, Stigliano L, Strippoli S, On Behalf Of The Italian Melanoma Intergroup Imi Study. No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. *Cancers (Basel)*. 2021 Jan 26;13(3):475. doi: 10.3390/cancers13030475. PMID: 33530579.

Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, **Ascierto PA**, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). *Nat Med*. 2021 Feb 8. doi: 10.1038/s41591-020-01188-3. Epub ahead of print. PMID: 33558722.

Grignani G, Chiaron Sileni V, Pinto C, Depenni R, Fazio N, Galli L, Giuffrida D, Carnaghi C, Ciliberto D, Corsi DC, Queirolo P, Benincasa E, Venturini F, Fazzi G, Costa N, **Ascierto PA**. Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. *J Transl Med*. 2021 Feb 15;19(1):70. doi: 10.1186/s12967-021-02730-8. PMID: 33588870.

Mandala M, Lorigan P, De Luca M, Bianchetti A, Merelli B, Bettini AC, Bonomi L, Nahm S, Vitale MG, Negrini G, Di Croce A, **Ascierto PA**, Rulli E, Tondini CA. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study. *J Immunother Cancer*. 2021 Feb;9(2):e001694. doi: 10.1136/jitc-2020-001694. PMID: 33593827.

Trojaniello C, Vitale MG, **Ascierto PA**. Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19. *Ann Oncol*. 2021 Feb 15;S0923-7534(21)00125-3. doi: 10.1016/j.annonc.2021.02.008. Epub ahead of print. PMID: 33600920.

Olofsson Bagge R, Ny L, **Ascierto PA**, Hodi FS, Larkin J, Robert C, Schachter J, Weber JS, Long GV, van Akkooi ACJ. The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. *Melanoma Res*. 2021 Feb 18. doi: 10.1097/CMR.0000000000000719. Epub ahead of print. PMID: 33625104.

Barbato A, Iuliano A, Volpe M, D'Alterio R, Brillante S, Massa F, De Cegli R, Carrella S, Salati M, Russo A, Russo G, Riccardo S, Cacchiarelli D, Capone M, Madonna G, **Ascierto PA**, Franco B, Indrieri A, Carotenuto P. Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma. *Int. J. Mol. Sci*. 2021, 22, 1801. <https://doi.org/10.3390/ijms22041801>

Atripaldi L, Sale S, Capone M, Montesarchio V, Parrella R, Botti G, **Ascierto PA**, Madonna G. Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave. *J Transl Med*. 2021 Mar 2;19(1):93. doi: 10.1186/s12967-021-02762-0. PMID: 33653336.

Vanella V, Festino L, Vitale MG, Alfano B, **Ascierto PA**. Emerging anti PD-1/PD-L1 antagonists for the treatment of malignant melanoma. *Expert Opin Emerg Drugs*. 2021 Mar 9. doi: 10.1080/14728214.2021.1901884. Epub ahead of print. PMID: 33686894.

Goldman JD, Ascierto PA. Perspectives on COVID-19 and cancer immunotherapy: a review series. *J Immunother Cancer*. 2021 Mar;9(3):e002489. doi: 10.1136/jitc-2021-002489. PMID: 33688023.

Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, Hassel JC, Weishaupt C, Eigentler T, Schilling B, Schummer P, Sirokay J, Kiecker F, Owen CN, Fleischer MI, Cann C, Kähler KC, Mohr P, Bluhm L, Niebel D, Thoms KM, Goldinger SM, Reinhardt L, Meier F, Berking C, Reinhard R, Susok L, **Ascierto PA**, Drexler K, Pföhler C, Tietze J, Heinzerling L, Livingstone E, Ugurel S, Long GV, Stang A, Schadendorf D, Zimmer L. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. *Eur J Cancer*. 2021 Mar 15;148:61-75. doi: 10.1016/j.ejca.2021.01.034. Epub ahead of print. PMID: 33735811.

Isgrò MA, Vitale MG, Celentano E, Nocerino F, Porciello G, Curvietto M, Mallardo D, Montagnese C, Russo L, Zanaletti N, Avallone A, Pensabene M, De Laurentiis M, Centonze S, Pignata S, Cannella L, Morabito A, Caponigro F, Botti G, Masucci GV, Giannarelli D, Cavalcanti E, **Ascierto PA**. Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis. *J Transl Med*. 2021 Mar 31;19(1):132. doi: 10.1186/s12967-021-02798-2. PMID: 33789686.

Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, Martínez-Vila C, Wallace R, Bhav P, Reijers I, Thompson N, Vanella V, Gerard C, Aspeslagh S, Labianca A, Khattak A, Mandala M, Xu W, Neyns B, Michielin O, Blank CU, Welsh SJ, Haydon A, Sandhu S, Mangana J, McQuade JL, **Ascierto PA**, Zimmer L, Johnson DB, Arance A, Lorigan P, Lebbé C, Carlino MS, Sullivan R, Long GV, Menzies AM. Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma. *Ann Oncol*. 2021 Mar 30;S0923-7534(21)01101-7. doi: 10.1016/j.annonc.2021.03.204. PMID: 33798657.

Cerino P, Coppola A, Volzone P, Pizzolante A, Pierri B, Atripaldi L, Zollo M, Capasso M, **Ascierto PA**, Triassi M, Brambilla G, Perrella A, Bruzzese D, Buonerba C. Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study. *Future Sci OA*. 2021 Jan 12;7(4):FSO673. doi: 10.2144/fsoa-2020-0203. PMID: 33815819; PMCID: PMC7802431.

Dimitriou F, Zaremba A, Allayous C, Kähler KC, Gerard CL, Festino L, Schäfer S, Toussaint F, Heinzerling L, Hassel JC, **Ascierto PA**, Michielin O, Hauschild A, Lebbe C, Livingstone E, Ramelyte E, Cheng PF, Dummer R, Mangana J. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. *Eur J Cancer*. 2021 Apr 2;149:37-48. doi: 10.1016/j.ejca.2021.02.037. Epub ahead of print. PMID: 33823361.

Ascierto PA, Atkins MB, Eggermont AM, Gershenwald JE, Grob JJ, Hamid O, Sondak VK, Sosman JA, Tawbi HA, Weber JS, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. *J Transl Med*. 2021 Apr 7;19(1):142. doi: 10.1186/s12967-021-02808-3. PMID: 33827575.

Ascierto PA, Brody J, Butterfield LH, Finn OJ, Goldberg J, Perrone F, Sullivan RJ, Fox BA, Hwu P, Puzanov I. The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020. *J Transl Med*. 2021 Apr 7;19(1):144. doi: 10.1186/s12967-021-02811-8. PMID: 33827609.

Ascierto PA, Fu B, Wei H. IL-6 modulation for COVID-19: the right patients at the right time? *J Immunother Cancer*. 2021 Apr;9(4):e002285. doi: 10.1136/jitc-2020-002285. PMID: 33837054; PMCID: PMC8042594.

Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, **Ascierto PA**, Rutkowski P, Schadendorf D, Koonstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreard S, Kicinski M, Suci S, Robert C; EORTC Melanoma Group. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncol*. 2021 Apr 12;S1470-2045(21)00065-6. doi: 10.1016/S1470-2045(21)00065-6. Epub ahead of print. PMID: 33857412.

Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, **Ascierto PA**, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koonstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreard S, Kicinski M, Suci S, Robert C, Eggermont AM; EORTC Melanoma Group. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncol*. 2021 Apr 12;S1470-2045(21)00081-4. doi: 10.1016/S1470-2045(21)00081-4. Epub ahead of print. PMID: 33857414.

Borzillo V, Di Franco R, Giannarelli D, Cammarota F, Scipilliti E, D'Ipollito E, Petito A, Serra M, Falivene S, Grimaldi AM, Simeone E, Festino L, Vanella V, Trojaniello C, Vitale MG, Madonna G, **Ascierto PA**, Muto P. Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. *Cancers (Basel)*. 2021 Apr 13;13(8):1857. doi: 10.3390/cancers13081857. PMID: 33924595; PMCID: PMC8068853.

Troiani T, De Falco V, Napolitano S, Trojaniello C, **Ascierto PA**. How we treat locoregional melanoma. *ESMO Open*. 2021 Apr 27;6(3):100136. doi: 10.1016/j.esmoop.2021.100136. Epub ahead of print. PMID: 33930656.

Versluis JM, Hendriks AM, Weppler AM, Brown LJ, de Joode K, Suijkerbuijk KPM, Zimmer L, Kapiteijn EW, Allayous C, Johnson DB, Hepner A, Mangana J, Bhav P, Jansen YJL, Trojaniello C, Atkinson V, Storey L, Lorigan P, **Ascierto PA**, Neyns B, Haydon A, Menzies AM, Long GV, Lebbe C, van der Veldt AAM, Carlino MS, Sandhu S, van Tinteren H, de Vries EGE, Blank CU, Jalving M. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. *Eur J Cancer*. 2021 May 7;151:72-83. doi: 10.1016/j.ejca.2021.04.003. Epub ahead of print. PMID: 33971447.

Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, **Ascierto PA**, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. *Lancet Oncol*. 2021 May 11;S1470-2045(21)00097-8. doi: 10.1016/S1470-2045(21)00097-8. Epub ahead of print. PMID: 33989557.

Simonetti I, Sandomenico F, Rocco MP, Fusco R, Setola SV, Granata V, Iasevoli DM, **Ascierto PA**, Grassi R, Petrillo A. Metastatic endo and perineural involvement of the ulnar nerve from malignant melanoma: ultrasound (US) and magnetic resonance imaging (MRI) findings. *Eur Rev Med Pharmacol Sci*. 2021 May;25(9):3478-3482. doi: 10.26355/eurrev_202105_25829. PMID: 34002821.

Scognamiglio G, Capone M, Sabbatino F, Di Mauro A, Cantile M, Cerrone M, Madonna G, Grimaldi AM, Mallardo D, Palla M, Sarno S, Anniciello AM, Di Bonito M, **Ascierto PA**, Botti G. The Ratio of GrzB+ – FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. *Cancers*. 2021; 13(10):2325. <https://doi.org/10.3390/cancers13102325>

Atkinson VG, Quaglino P, Aglietta M, Del Vecchio M, Depenni R, Consoli F, Bafaloukos D, Ferrucci PF, Tulyte S, Krajsová I, **Ascierto PA**, Gueli R, Arance A, Gogas H, Banerjee H, Saliba T, de Jong E, Neyns B. A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). *Cancers (Basel)*. 2021 May 18;13(10):2466. doi: 10.3390/cancers13102466. PMID: 34070224.

Ascierto PA, Bifulco C, Ciardiello F, Demaria S, Emens LA, Ferris R, Formenti SC, Galon J, Khleif SN, Kirchhoff T, McQuade J, Odunsi K, Patnaik A, Paulos CM, Taube JM, Timmerman J, Fox BA, Hwu P, Puzanov I. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). *J Transl Med*. 2021 Jun 2;19(1):238. doi: 10.1186/s12967-021-02895-2. PMID: 34078406.

Gogas H, Dummer R, **Ascierto PA**, Arance A, Mandalà M, Liskay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Sileni VC, Dutriaux C, Yamazaki N, Loquai C, Queirolo P, Jan de Willem G, Sellier AT, Suissa J, Murriss J, Gollerkeri A, Robert C, Flaherty KT. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). *Eur J Cancer*. 2021 Jun 3;152:116-128. doi: 10.1016/j.ejca.2021.04.028. Epub ahead of print. PMID: 34091420.

Ascierto PA, Dreno B, Larkin J, Ribas A, Liskay G, Maio M, Mandal M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Atkinson V, Dutriaux C, Garbe C, Hsu JJ, Jones S, Li H, McKenna E, Voulgari A, McArthur GA. 5-Year Outcomes with Cobimetinib Plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-Up of the coBRIM Study. *Clin Cancer Res*. 2021 Jun 22:clincanres.0809.2021. doi: 10.1158/1078-0432.CCR-21-0809. Epub ahead of print. PMID: 34158360.

Santini D, Zeppola T, Russano M, Citarella F, Anesi C, Buti S, Tucci M, Russo A, Sergi MC, Adamo V, Stucci LS, Bersanelli M, Mazzaschi G, Spagnolo F, Rastelli F, Giorgi FC, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Pala L, Queirolo P, Bracarda S, Macrini S, Gori S, Inno A, Zoratto F, Tanda ET, Mallardo D, Vitale MG, Talbot T, **Ascierto PA**, Pinato DJ, Ficorella C, Porzio G, Cortellini A. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. *J Transl Med*. 2021 Jun 24;19(1):270. doi: 10.1186/s12967-021-02937-9. PMID: 34167578.

Brahmer JR, Abu-Sbeih H, **Ascierto PA**, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomaso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. *J Immunother Cancer*. 2021 Jun;9(6):e002435. doi: 10.1136/jitc-2021-002435. PMID: 34172516.

Trojaniello C, Luke JJ, **Ascierto PA**. Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. *Front Oncol*. 2021 Jun 10;11:670726. doi: 10.3389/fonc.2021.670726. PMID: 34178657; PMCID: PMC8222774.

Dearden H, Au L, Wang DY, Zimmer L, Eroglu Z, Smith JL, Cuvietto M, Khoo C, Atkinson V, Lo S, Long GV, Sandhu S, **Ascierto PA**, Carlino MS, Johnson DB, Larkin J, Menzies AM. Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. *Eur J Cancer*. 2021 Jun 25;153:168-178. doi: 10.1016/j.ejca.2021.04.045. Epub ahead of print. PMID: 34182268.

Giugliano F, Crimini E, Tarantino P, Zagami P, Uliano J, Corti C, Trapani D, Curigliano G, **Ascierto PA**. First line treatment of BRAF mutated advanced melanoma: Does one size fit all? *Cancer Treat Rev*. 2021 Jun 18;99:102253. doi: 10.1016/j.ctrv.2021.102253. Epub ahead of print. PMID: 34186441.

H. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol*. 2022 Aug 5:S1470-2045(22)00452-1. doi: 10.1016/S1470-2045(22)00452-1. Epub ahead of print. PMID: 35940183.

Larkin J, Weber J, Del Vecchio M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, De la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Long GV, Lobo M, Askelson M, **Ascierto PA**, Mandalá M. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. *Eur J Cancer*. 2022 Aug 11;173:285-296. doi: 10.1016/j.ejca.2022.06.041. Epub ahead of print. PMID: 35964471.

Cristinziano L, Modestino L, Capone M, Madonna G, Mallardo D, Giannarelli D, D'Angelo G, Ferrara AL, Loffredo S, Varricchi G, Vanella V, Festino L, **Ascierto PA**, Galdiero MR. PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab. *Front Immunol*. 2022 Aug 9;13:962669. doi: 10.3389/fimmu.2022.962669. PMID: 36016960; PMCID: PMC9398490.

Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbè C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzales Cao M, Minisini AM, De Placido S, Sannamed MF, Mallardo D, Curvietto M, Melero I, Palmieri G, Grimaldi AM, Giannarelli D, Dummer R, Chiarion-Sileni V. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. *J Clin Oncol*. 2022 Sep 1:JCO2102961. doi: 10.1200/JCO.21.02961. Epub ahead of print. PMID: 36049147.

Ascierto PA, Agarwala SS, Blank C, Caracò C, Carvajal RD, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Grob JJ, Hamid O, Krosgaard M, Lo RS, Lund AW, Madonna G, Michielin O, Neyns B, Osman I, Peters S, Poulikakos PI, Quezada SA, Reinfield B, Zitvogel L, Puzanov I, Thurin M. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). *J Transl Med*. 2022 Sep 4;20(1):391. doi: 10.1186/s12967-022-03592-4. PMID: 36058945.

Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Hirohashi Y, Furuhashi T, Takemasa I, Patel P, Vora H, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Yoshino T, Taniguchi H, Bifulco C, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert CI, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Joret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang J, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson E, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dunder P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Marliot F, Fredriksen T, Buttard B, Lafontaine L, Maby P, Majidi A, Hijazi A, El Sissy C, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, Van de Water C, van Lent-van Vliet S, Knijn N, Muşin A, *Scripcariu DV, Marincola FM, Ascierto PA*, Fox BA, Pagès F, Kawakami Y, Galon J. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study. *Cancers (Basel)*. 2022 Sep 6;14(18):4346. doi: 10.3390/cancers14184346. PMID: 36139506; PMCID: PMC9497086.

Horgan D, Baird AM, Middleton M, Mihaylova Z, Van Meerbeeck JP, Vogel-Claussen J, Van Schil PE, Malvey H, **Ascierto PA**, Dube F, Zaiac M, Lal JA, Kamińska-Winciorek G, Donia M, André T, Zozaric M, Osterlund P, Dumitrascu DL, Bertolaccini L. How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma? Healthcare (Basel). 2022 Aug 25;10(9):1618. doi: 10.3390/healthcare10091618. PMID: 36141230; PMCID: PMC9498919.

Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, **Ascierto PA**, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). *J Clin Oncol*. 2022 Sep 26:JCO2200533. doi: 10.1200/JCO.22.00533. Epub ahead of print. PMID: 36162037.

Atkins MB, Abu-Sbeih H, **Ascierto PA**, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Gretten

TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzearella L, Ramalingam SS, Regan MM, Rini BI, Sznol M. Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). *J Immunother Cancer*. 2022 Sep;10(9):e005413. doi: 10.1136/jitc-2022-005413. PMID: 36175037; PMCID: PMC9528604.

Mallardo D, Simeone E, Vanella V, Vitale MG, Palla M, Scarpato L, Paone M, De Cristofaro T, Borzillo V, Cortellini A, Sparano P, Pignata S, Fiore F, Caracò C, Maiolino P, Petrillo A, Cavalcanti E, Lastoria S, Muto P, Budillon A, Warren S, **Ascierto PA**. Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization. *J Transl Med*. 2022 Sep 30;20(1):436. doi: 10.1186/s12967-022-03643-w. PMID: 36180872; PMCID: PMC9523893.

Khattak MA, Luke JJ, Long GV, **Ascierto PA**, Rutkowski P, Schadendorf D, Robert C, Grob JJ, de la Cruz Merino L, Del Vecchio M, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Carlino MS, Mohr P, De Galitiis F, Ross MI, Eroglu Z, Chen K, Jiang R, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Kirkwood JM. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. *Eur J Cancer*. 2022 Nov;176:207-217. doi: 10.1016/j.ejca.2022.08.004. Epub 2022 Oct 3. PMID: 36202690.

Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, **Ascierto PA**; KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. *Lancet Oncol*. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18. PMID: 36265502.

Carotenuto P, Romano A, Barbato A, Quadrano P, Brillante S, Volpe M, Ferrante L, Tammaro R, Capleo M, De Cegli R, Iuliano A, Testa M, Andreone F, Ciliberto G, Clery E, Troncone G, Palma G, Arra C, Barbieri A, Capone M, Madonna G, **Ascierto PA**, Lanfranccone L, Indrieri A, Franco B. Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma. *Cell Rep*. 2022 Nov 8;41(6):111601. doi: 10.1016/j.celrep.2022.111601. PMID: 36351409.

Ruggiero CF, Fattore L, Terrenato I, Sperati F, Salvati V, Madonna G, Capone M, Valenti F, Di Martino S, Mandoj C, Liguoro D, Castaldo V, Cafaro G, Simeone E, Vanella V, Russillo M, Conti L, Cuda G, Giannarelli D, **Ascierto PA**, Mancini R, Ciliberto G. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma. *Theranostics* 2022; 12(17):7420-7430. doi:10.7150/thno.77761.

Ascierto PA, Schadendorf D. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma. *J Immunother Cancer*. 2022 Dec;10(12):e005082. doi: 10.1136/jitc-2022-005082. PMID: 36455990; PMCID: PMC9716987.

Ascierto PA, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Zhukova N, Schachter J, Yan Y, Caro I, Hertig C, Xue C, Kusters L, McArthur GA, Gutzmer R. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. *Lancet Oncol*. 2023 Jan;24(1):33-44. doi: 10.1016/S1470-2045(22)00687-8. Epub 2022 Nov 29. PMID: 36460017.

Lee J, Ahmed T, Maurichi A, Di Guardo L, Stagno AM, Warburton L, Taylor AM, Livingstone E, Rehman S, Khattak A, Kahler KC, Vanella V, Atkinson V, Millward M, Schadendorf D, Johnson DB, **Ascierto PA**, Hauschild A, Lo SN, Long GV, Menzies AM, Carlino MS. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. *Eur J Cancer*. 2023 Jan;179:87-97. doi: 10.1016/j.ejca.2022.11.009. Epub 2022 Nov 12. PMID: 36509002.

Aurisicchio L, Brambilla N, Cazzaniga ME, Bonfanti P, Milleri S, **Ascierto PA**, Capici S, Vitalini C, Girolami F, Giacobelli G, Caselli G, Visintin M, Fanti F, Ghirri M, Conforti A, Compagnone M, Lione L, Salvatori E, Pinto E, Muzi A, Marra E, Palombo F, Roscilli G, Manenti A, Montomoli E, Cadossi M, Rovati LC. A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19. *Mol Ther*. 2022 Dec 27:S1525-0016(22)00753-5. doi: 10.1016/j.ymthe.2022.12.017. Epub ahead of print. PMID: 36575794; PMCID: PMC9792419.

Long GV, Luke JJ, Fukunaga-Kalabis M, **Ascierto PA**. Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma - Authors' reply. *Lancet Oncol*. 2023 Jan;24(1):e8. doi: 10.1016/S1470-2045(22)00753-7. PMID: 36603931.

Mlecnik B, Lugli A, Bindea G, Marliot F, Bifulco C, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert CI, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang J, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzella L, Konopasek B, Dunder P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Lafontaine L, Maby P, Majdi A, Hijazi A, El Sissy C, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, van de Water C, Vliet SVL, Knijn N, Mušinā AM, *Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhashi T, Takemasa I, Patel P, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA*, Fox BA, Pagès F, Galon J. Multicenter International Study of the Consensus Immunoscope for the Prediction of Relapse and Survival in Early-Stage Colon Cancer. *Cancers (Basel)*. 2023 Jan 8;15(2):418. doi: 10.3390/cancers15020418. PMID: 36672367; PMCID: PMC9856473.

Granata V, Fusco R, Setola SV, Simonetti I, Picone C, Simeone E, Festino L, Vanella V, Vitale MG, Montanino A, Morabito A, Izzo F, **Ascierto PA**, Petrillo A. Immunotherapy Assessment: A New Paradigm for Radiologists. *Diagnostics (Basel)*. 2023 Jan 13;13(2):302. doi: 10.3390/diagnostics13020302. PMID: 36673112; PMCID: PMC9857844.

Núñez NG, Berner F, Friebe E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, **Ascierto PA**, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. *Med (N Y)*. 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23. PMID: 36693381.

Egeler MD, van Leeuwen M, Fraterman I, van den Heuvel NMJ, Boekhout AH, Lai-Kwon J, Wilthagen EA, Eriksson H, Haanen JB, Wilgenhof S, **Ascierto PA**, van Akkooi ACJ, van de Poll-Franse LV. Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review. *Crit Rev Oncol Hematol*. 2023 Feb 1;183:103919. doi: 10.1016/j.critrevonc.2023.103919. Epub ahead of print. PMID: 36736511.

DI Cosola M, Spirito F, Saracino P, Caponio VC, Diaz-Flores Garcia V, Madonna G, **Ascierto P**, Lo Muzio L. Oral immune-related adverse events caused by immune checkpoint inhibitors: a retrospective study. *Minerva Dent Oral Sci*. 2022 Dec;71(6):318-323. doi: 10.23736/S2724-6329.22.04768-4. PMID: 36760201.

Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D,

Dolfi S, Mitra P, Suryawanshi S, Grob JJ. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. *J Clin Oncol*. 2023 Feb 13;JCO2202072. doi: 10.1200/JCO.22.02072. Epub ahead of print. PMID: 36780608.

Mallardo D, Simeone E, Festino L, Tuffanelli M, Vanella V, Trojaniello C, Vitale MG, Ottaviano M, Capone M, Madonna G, Sparano F, Cioli E, Scarpato L, Palla M, Di Trollo R, Meinardi P, Caracò C, Ferrara G, Muto P, Cavalcanti E, **Ascierto PA**. IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab. *J Transl Med*. 2023 Feb 23;21(1):140. doi: 10.1186/s12967-023-03971-5. PMID: 36823670; PMCID: PMC9948392.

Weppeler AM, Da Meda L, Pires da Silva I, Xu W, Grignani G, Menzies AM, Carlino MS, Long GV, Lo SN, Nordman I, Steer CB, Lyle M, Trojaniello C, **Ascierto PA**, Lebbe C, Sandhu S. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. *Eur J Cancer*. 2023 Jan 30;183:109-118. doi: 10.1016/j.ejca.2023.01.016. Epub ahead of print. PMID: 36842413.

Ascierto PA, Cioli E, Chiarion-Sileni V, Quaglini P, Spagnolo F, Guidoboni M, Del Vecchio M, Peris K, Queirolo P, Fioretto L, Caracò C, Paone M, Sorrentino A, Capone M, Giannarelli D, Ferrara G, Massi D, Trojaniello C. Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study. *Front Oncol*. 2023 Feb 9;13:1107307. doi: 10.3389/fonc.2023.1107307. PMID: 36845751; PMCID: PMC9949553.

Costantini S, Madonna G, Di Gennaro E, Capone F, Bagnara P, Capone M, Sale S, Nicastro C, Atripaldi L, Fiorentino G, Parrella R, Montesarchio V, Atripaldi L, **Ascierto PA**, Budillon A. New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer. *Int J Mol Sci*. 2023 Mar 3;24(5):4922. doi: 10.3390/ijms24054922. PMID: 36902351; PMCID: PMC10003544.

Monfrecola G, Fornaro L, **Ascierto PA**, Scarpato L, Anniciello AM, Fabbrocini G, Marasca C. Could wide tattoo delay the early diagnosis of cutaneous melanoma? *J Eur Acad Dermatol Venereol*. 2023 Mar 13. doi: 10.1111/jdv.19037. Epub ahead of print. PMID: 36912734

Projects

Research Projects Ongoing or Completed: Ministry of Health: Research fund year 1995 Meccanismi molecolari di differenziazione del danno cellulare. Principal Investigator: G. Castello, MD Dr. Ascierto will participate on the Ministry of Health grant as a Sub_Investigator. □ Ministry of Health: Research fund year 1997 Approccio biomolecolare alla terapia del melanoma cutaneo. Principal Investigator: G Castello, MD Dr. Ascierto will participate on the Ministry of Health grant as a Sub_Investigator. □ Ministry of Health: Research fund year 1998 Basi genetiche della suscettibilità al melanoma maligno: studio della predisposizione e ricorrenza familiare e definizione dei fattori di rischio e prognosi. Principal Investigator: G Castello, MD Dr. Ascierto will participate on the Ministry of Health grant as a Co_Investigator. □ Ministry of Health: Research fund year 1999 Basi molecolari della trasformazione e progressione neoplastica nel melanoma maligno: utilizzo di nuove metodiche di analisi citogenetica per la valutazione di specifiche alterazioni geniche correlate all'outcome clinico. Principal Investigator: ML Lombardi, PhD Dr. Ascierto will participate on the Ministry of Health grant as a Co_Investigator. □ Ministry of Health: Research fund year 2000 Effetti di campi elettromagnetici sulla dinamica molecolare di strutture biologiche e conseguenti implicazioni funzionali. Principal Investigator: G Castello, MD Dr. Ascierto will participate on the Ministry of Health grant as a Sub_Investigator. □ Fifth Framework Programme of the European Community for Research: Technological Development and Demonstration activities _ Cooperative Research Craft "GENOSENSE (Development of an innovative genotoxicity measuring device to facilitate the safety control in food products and pharmaceuticals". Principal Investigator: G Castello, MD Dr. Ascierto will participate on the Ministry of Health grant as a Co_Investigator. □ Ministry of Health: Research fund year 2003 Studio della trasformazione e progressione neoplastica nel melanoma: nuovi bersagli molecolari ad uso diagnostico e terapeutico. Principal Investigator: PA Ascierto, MD □ Ministry of Health: Research fund year 2005 Valutazione post terapia della immunosoppressione tumorale in pazienti affetti da neoplasia in fase avanzata. Principal Investigator: PA Ascierto, MD □ Italian National Institute of Health: Research fund year 2007 Promozione della ricerca clinica nel settore delle bioterapie antitumorali e sviluppo di vaccini cellulari basati sull'uso di cellule dendritiche e di nuovi antigeni tumorali. Principal Investigator: PA Ascierto, MD □ Italian National Institute of Health and Ministry of Health (Alliance Against Cancer): Research fund year 2007 □ Rete nazionale per studi clinici e di strutture GMP per le bioterapie dei tumori: Sviluppo di documenti consensus, di linee guida e documenti divulgativi degli aspetti regolatori. Informazioni sulla normativa (Help Desk). Principal Investigator: PA Ascierto, MD □ BMS II_O network project 2012: Immunoscoring in Melanoma. Principal Investigator: PA Ascierto, MD □ Ventana project 2012_2015: Evaluation of a multiplex staining in lymph node from melanoma patient underwent to lymphectomy. Principal Investigator: PA Ascierto, MD □ ERA_NET on Translational Cancer Research (TRANSCAN): Research fund year 2013 Project code: RRC_2014_2354557. Project title: Integrative cancer immunology and Immunoscoring for cancer classification and immunotherapies (IMMUNOSCOR). Principal Investigator: PA Ascierto, MD □ Ministry of Health: Research fund year 2013 Project title: New Possible Approach for the Classification of Melanoma and Prediction of Response to Immunotherapy: Im_munoscore and Immune Profiling. Principal Investigator: PA Ascierto, MD Principal Investigator for the following clinical trials: □ Multicenter Double_Blind Phase 3 Trial of Canvaxin vs Placebo as Post Surgical Adjuvant in Metastatic Melanoma. [Multicenter Melanoma Active Immunotherapy Trials (MMAIT)]. □ Phase I/II Study of Treatment of Subjects with Metastatic Melanoma with Pegylated Arginine Deiminase (ADI_PEG 20). (First in human). □ Randomized, open phase II study of immunization with the recombinant MAGE_3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma. (EORTC 16032_18031). □ Adjuvant Peg_Intron Treatment in Stage III Melanoma. Peg_Intron versus Observation after Regional Lymph Node Dissection in AJCC Stage III (TxN1_2M0) Melanoma Patients. A Randomized Phase III Trial. (EORTC 18991). □ Adjuvant ganglioside GM2_KLH/QS_21 Vaccination Postoperative adjuvant ganglioside GM2_KLH/QS_21 vaccination treatment vs observation after resection of primary cutaneous melanoma (AJCC stage II, T3_T4N0M0), a 2_arm multicenter randomized phase III trial". (EORTC 18961). □ Intravenous versus intra_arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma : a randomized phase III study of the EORTC Melanoma Group. (EORTC 18021). □ A multi_center single arm phase II study of MDX_010 (BMS_734016) monotherapy in patients with treated unresectable melanoma. (Bristol CA 184008). □ Phase 3, Open Label, Randomized, Comparative Study of Tivolumab and Either Dacarbazine or Temozolomide in Patients with Advanced Melanoma". (Pfizer A3671009). □ A multi_center RANDOMIZED, double blind arm, two_arm, phase III study in patients with untreated Stage III (unresectable) or IV melanoma. Receiveiv Dacarbazine Plus 10 mg/Kg of Ipilimumab (MDX_010) vs Dacarbazine plus Placebo. (CA 184024). □ A randomized multi_dose open label, phase II study of BMS 663513 as a second -line monotherapy in subjects with previously treated unresectable stage III or stage IV melanoma. (Bristol CA186006). □ A multicenter, randomized double_bind study of dacarbazine with or without Genasense in chemotherapy_naive subjects with advanced melanoma and low LDH. (Agenda Trial GM307). □ Adjuvant immunotherapy with monoclonal anti_CTLA_4 (Ipilimumab) vs placebo after complete resection of melanoma in high_risk stage III: A randomized double_blind phase III EORTC Melanoma Group (CA184_029 / EORTC 18071). □ A phase III clinical trial to evaluate the safety and efficacy of treatment with 2 mg intralesional Allovectin_7 compared to dacarbazine (DTIC) or Temozolomide (TMZ) in subjects with recurrent metastatic melanoma. (VICAL LX01_315). □ Analysis of the expression of a specific set of genes and tumor antigens in patients with non -small cell lung cancer and melanoma. (GSK Onco RD001). □ A double blind , randomized , placebo - controlled Phase III study to assess the efficacy of rec_mage -A3 + AS15 ASCI as adjuvant therapy in patients with Mage - A3 - positive resected melanoma. (GSK DERMA). □ A Randomized, Double_Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel (CA184043). □ A Multicenter, Randomized, Double_blinded, Controlled, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma with V600E_Positive BRAF Mutation Receiving RO5185426 or Dacarbazine (BRIM3). □ An open, single_arm trial to assess the clinical activity of recMAGE_A3 + AS15 in patients with unresectable

MAGE_A3_positive metastatic cutaneous melanoma (PREDICT). □ An Open_Label, Multicenter, Phase III Trial of ABI_007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma (CA033). □ A Phase II (GSK BRF113710) single_arm, open_label study of GSK2118436 in previously treated BRAF mutant metastatic melanoma. □ A Phase II (GSK BRF113929) open_Label, Two_Cohort, Multicentre Study of GSK2118436 a Single Agent in Treatment Naive and Previously Treated Subjects with BRAF Mutation_Positive Metastatic Melanoma □ A Randomized Double_Blind Phase III study of Ipilimumab Administered at 3 mg/kg at 10 mg/kg in Subjects with previously Treated or Untreated unresectable or Metastatic Melanoma (CA184_169) □ A phase II, randomized double_blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma (CLDE225A2201) □ Open_Label study, Phase II, to evaluate the safety and efficacy of MEK 162 administered orally in adult patients with cutaneous malignant melanoma and locally advanced unresectable or metastatic, with BRAF V600E or NRAS mutations (CMEK162X2201) □ A Phase II Study of the Combination of Ipilimumab and Fotemustine in Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma (NIBIT_M1) □ Study the dose_setting and evaluation of the activity of the fusion protein tumor_specific cytokine monoclonal antibody L191L2 in combination with dacarbazine in patients with Metastatic Melanoma (L191L2/Dacarbazine) □ Phase III, prospective, multicenter, randomized in open to active treatment, two parallel group study to compare the efficacy and safety of masitinib to 7.5 mg / kg / day versus dacarbazine in the treatment of patients with melanoma the unresectable or metastatic stage 3 or stage 4, which has a mutation in the domain of C_KIT juxta membranario. (AB08026). □ Realization of a national clinical registry Melanoma (CNMR). □ An open_label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma (MO25515). □ A multicenter study on the electro_chemotherapy in patients with metastatic cutaneous and subcutaneous unresponsive or not candidates to conventional treatments. □ Open_label study, multicenter, randomized, Phase Ib/II of E7080 in combination with dacarbazine compared with dacarbazine monotherapy as first_line treatment in patients with stage IV melanoma (E7080_702). □ Multicenter, randomized, open_label, two treatment arms, Phase III, to compare the efficacy of Tasigna versus dacarbazine in the treatment of Patients with Metastatic Melanoma and / or inoperable which has C_KIT mutation. (CAMN107B2301). □ A single arm, open_label, phase II, multicenter study to assess the safety of vismodegib (GDC_0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC) (MO25616). □ A Randomized Double_Blind Phase III Study of Ipilimumab Administered at 3 mg/kg vs at 10 mg/kg in Subjects with Previously Treated or Untreated Unresectable or Metastatic Melanoma. (CA184169). □ A phase III, randomised, open_label study comparing the combination of the BRAF inhibitor, GSK2118436 and the MEK inhibitor, GSK1120212 to the BRAF inhibitor vemurafenib in subjects with advanced (stage IIIc) or metastatic (stage IV) BRAF V600E/K mutation positive melanoma (Combo V). □ Phase III, randomized, double_blind, placebo controlled study of vemurafenib (RO5185426) adjuvant therapy in patients with surgically_resected, cutaneous BRAF mutant melanoma at high risk for recurrence (BRIM_8). □ CA209_037 study: A Randomized, Open_Label Phase 3 Trial of BMS_936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti_CTLA_4 Therapy. □ G028141 study (Co_BRIM): A Phase 3 Study Comparing GDC_0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma. □ EMR200066_007 study: A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib (MSC1936369B, formerly known as AS703026) or dacarbazine in previously untreated subjects with NRAS mutated locally advanced or metastatic malignant melanoma. □ CA209066 study: A Phase 3, Randomized, Double_Blind Study of BMS_936558 vs Dacarbazine in Subjects with Previously Untreated Unresectable or Metastatic Melanoma. □ MK_3475_002 study: A Double_Blind, Randomized, Phase II Study of MK_3475 versus Chemotherapy in Patients with Ipilimumab Refractory Advanced Melanoma. □ MK3475_054: Study of Pembrolizumab (MK_3475) Versus Placebo After Complete Resection of High_Risk Stage III Melanoma (MK_3475_054/KEYNOTE_054) □ C12_315_03: Dose Escalation Study of LTX_315 in Patients With Transdermally Accessible Tumours □ MK3475_158: Study of Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_3475_158/KEYNOTE_158) □ 20120325: Single_arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma □ CPDR001X2101: Phase I/II Study of PDR001 in Patients With Advanced Malignancies □ CA209_511: A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma □ EMR 200647_001: MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors □ SECOMBIT: Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (SECOMBIT) □ MK3475_252: A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma □ CA209_401: Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First_Line Treatment for Patients With Advanced Melanoma □ IMCgp100_201 : Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma □ Vemures Prognostic And Functional Significance Of Pd_L1 Expression In Metastatic Melanoma □ 2015_001/ MI29968 Studio Multicentrico, A Singolo Braccio, Fase II, Per Valutare Efficacia E Sicurezza Di Vismodegib E Radioterapia In Pazienti Affetti Da Carcinoma Basocellulare Ad Alto Rischio Di Recidiva O Localmente Avanzato Non Suscettibile Di Chirurgia Radicale (Virgilio). □ Uno Studio Di Fase 1/2, In Aperto, First_In_Human , Per Valutare La Sicurezza, La Farmacocinetica, La Farmacodinamica E L'attività Clinica Di Jnj_63723283, Un Anticorpo Monoclonale Anti_Pd_1, Nei Soggetti Con Cancro Di Stadio Avanzato □ Wp29945 Studio Di Fase Ib, In Aperto, Multicentrico, Con Incremento Progressivo Della Dose Ed Espansione Volto A Valutare La Sicurezza, La Farmacocinetica E L'attività Terapeutica Di Ro6958688 In Associazione Ad Atezolizumab In Pazienti Affetti Da Tumori Solidi Cea_Positivi Localmente Avanzati E/O Metastatici □ Bp29541 Studio Di Fase I, In Aperto, Multicentrico, Con Incremento Progressivo Della Dose, Volto A Valutare La Sicurezza, La Farmacocinetica E L'attività Terapeutica Di Ro6958688, Un Nuovo Anticorpo Linfociti T Bispecifico Che Agisce Selettivamente Sull'antigene Carcinoembrionario (Cea) Umano Espresso Sulle Cellule Neoplastiche E Sull'antigene Cd3 Presente Sui Linfociti T, Somministrato Per Via Endovenosa In Pazienti Affetti Da Tumori Solidi Cea_Positivi Localmente Avanzati E/O Metastatici □ CA209_915 Studio Di Fase 3, Randomizzato, Di Immunoterapia Aduvante Di Nivolumab In Combinazione Con Ipilimumab Rispetto Ad Ipilimumab O Nivolumab In Monoterapia Dopo Completa Resezione Di Melanoma In Stadio Iiib/C/D O Stadio Iv □ CA209_9GW Studio Di Fase 1/2 Per Valutare La Sicurezza E L'efficacia Preliminare Di Nivolumab Associato A Daratumumab In Pazienti Affetti Da Tumori Solidi Avanzati O Metastatici □ R2810_ONC_1620 Studio Di Fase 2 Di REGN2810, Un Anticorpo Monoclonale Interamente Umano Verso La Morte Cellulare Programmata_1, In Pazienti Con Carcinoma Basocellulare Avanzato Che Hanno Manifestato Progressione Della Malattia Con La Terapia Di Inibizione Della Via Di Segnalazione Hedgehog, O Erano Intolleranti Alla Precedente Terapia Di Inibizione Della Via Di Segnalazione Hedgehog □ IEO 523 Studio Interventistico, Multicentrico, In Aperto, Non Randomizzato Di Fase II Con Pembrolizumab Con Elettrochemioterapia In Pazienti Con Melanoma Non Operabile Con Metastasi Superficiali O Superficiali E Viscerali □ CO39722 Studio Di Fase Iii, In Aperto, Multicentrico, A Due Bracci, Randomizzato Per Valutare L'efficacia E La Sicurezza Di Cobimetinib Piu' Atezolizumab, Rispetto A Pembrolizumab, In Pazienti ConMelanoma Bravf600 Wild_Type Avanzato, Precedentemente Non Trattato □ C_144_01 Studio Multicentrico Di Fase 2 Per Valutare L'efficacia E La Sicurezza Di Linfociti Autologhi Infiltranti Il Tumore (LN_144) Per Il Trattamento Di Pazienti Con Melanoma Metastatico □ 21/17 Oss Fattori Tumorali_Intrinseci, Germinali E Ambientali Di Risposta All'immunoterapia In Pazienti Con Malattia Oncologica Avanzata. □ MFAG 2017 Ruolo Del Pathway L_Cisteina/H2S Nell'attività Immunosoppressiva Delle Mdscs Nel Melanoma □ CA017055 Studio Di Fase III Randomizzato, In Doppio Cieco, Di BMS_986205 In Combinazione Con Nivolumab Rispetto A Nivolumab In Partecipanti Affetti Da Melanoma Metastatico O Non Resecabile, Non Precedentemente Trattato. □ CDRB436BIT03 Analisi Retrospectiva Dei Dati Di Pazienti Affetti Da Melanoma Con Mutazione BRAF V600 In Stadio Avanzato O Metastatico Trattati Con La Terapia Di Combinazione Dabrafenib E Trametinib In Italia Nell'ambito Del □ CDRB436B2404 Esame Retrospectivo Di Cartelle Cliniche Per Ia Valutazione Di Dabrafenib In Monoterapia E/O Dell'associazione Dabrafenib_Trametinib In Pazienti Affetti Da Melanoma Metastatico, Allo Scopo Di Caratterizzare I Pazienti Con Beneficia A Lungo Termine Nel Programma Per Singoli Pazienti (IPP, Individual Patient Program) □ 16_214_02 Studio Di Fase 1/2, In Aperto, Multicentrico Sulla Combinazione Di NKTR_214 E Nivolumab O Sulla Combinazione Di NKTR_214, Nivolumab E Ipilimumab In Pazienti Con Determinate Neoplasie Maligne Solide Localmente Avanzate O Metastatiche □ CA224_047 Studio Di Fase 2/3 Randomizzato, In Doppio Cieco, Di Relatimab In Combinazione Con Nivolumab Rispetto A Nivolumab In Partecipanti Affetti Da Melanoma Metastatico O Non Resecabile, Non Precedentemente Trattato □ 2125_MEL_301 Confronto Randomizzato Di Fase 3 Di IMO_2125 Con Ipilimumab Rispetto A Ipilimumab In Monoterapia In Soggetti Affetti Da Melanoma Refrattario A Terapia Anti_PD1 □ CA022_001 Studio Di Fase 1/2 A, Prima Somministrazione Nell'uomo, Dell'anticorpo Monoclonale BMS_986218 Da Solo Ed In Combinazione Con Nivolumab In Tumori Solidi In Stadio Avanzato. □ I_Tackle Immunoterapia Seguita Dal Trattamento Con Inibitore EGFR In Pazienti Con Carcinoma Cutaneo Squamoso Localmente Avanzato O Metastatico: Combattere La Resistenza Primaria E Secondaria- I_TACKLE □

E7080_0081_116 Studio Clinico In Aperto Di Fase 1b Con Lenvatinib Più Pembrolizumab In Pazienti Affetti Da Carcinoma Epatocellulare □ MK3475_587 Sperimentazione Di Estensione Di Fase III, Multicentrica, In Aperto Per Valutare La Sicurezza E L'efficacia A Lungo Termine In Pazienti Con Tumori Avanzati Attualmente In Trattamento O In Follow-Up In Una Sperimentazione Con Pembrolizumab. □ SENSITIZE Studio In Aperto, Multicentrico, Di Fase Ib/II Di 4SC_202 In Combinazione Con Pembrolizumab In Pazienti Con Melanoma Cutaneo, Di Stadio III Non Resecabile O IV Metastatico, Refrattari Primari/Non Responsivi A Precedente Terapia Con Anti_PD_1. Studio SENSITIZE. □ CDRB436F2410 Studio In Aperto, Di Fase Iiib Con Dabrafenib In Combinazione Con Trametinib Nel Trattamento Adiuvante Del Melanoma In Stadio III Positivo Per La Mutazione BRAF V600 Dopo Resezione Completa, Per Valutare L'impatto Sugli Esiti Correlati Alla Piressia Di Un Algoritmo Per La Gestione Degli Eventi Avversi Adattato Alla Piressia □ MK3475_716 Terapia Adiuvante Con Pembrolizumab Versus Placebo In Pazienti Con Melanoma Di Stadio II Ad Alto Rischio E Resecato: Uno Studio Di Fase III Randomizzato E In Doppio Cieco (KEYNOTE 716) □ MO39136 Studio Di Fase Ii A Due Coorti Volto A Valutare La Sicurezza E L'efficacia Di Cobimetinib + Atezolizumab Nel Melanoma Wild_Type Con Metastasi A Carico Del Sistema Nervoso Centrale E Di Cobimetinib + Atezolizumab E Vemurafenib Nel Melanoma Positivo Per Mmutazione Di Brafv600 Con Metastasi A Carico Del Sistema Nervoso Centrale □ CA209_848 Studio Clinico Di Fase Ii, In Aperto, Randomizzato Di Nivolumab In Combinazione Con Ipilimumab O Nivolumab In Monoterapia In Pazienti Con Tumori Solidi Metastatici O Avanzati Con Un Alto Carico Mutazionale Del Tumore (Tmb_H) □CA045_001 Studio Di Fase 3, Randomizzato, In Aperto, Di NKTR_214 In Combinazione Con Nivolumab Rispetto A Nivolumab In Partecipanti Affetti Da Melanoma Metastatico O Non Resecabile, Non Precedentemente Trattato

Memberships

Active member of: Associazione Italiana di Oncologia Medica (AIOM _ Italian Society of Medical Oncology), American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), European Organization for Research and Treatment of Cancer (EORTC), Society of Immunotherapy of Cancer (SITC), Italian Network on Bioimmunotherapy of Tumors (NIBIT). Awards and Other Professional Activities: Coordinator of Melanoma Cooperative Group of Naples 1996_2007 Member of Scientific Committee of National Cancer Institute of Naples 2001_2007 Member of Board Committee of Italian Melanoma Intergroup (IMI) 2001_2004 Chair of the Interdepartmental Unit Melanoma at NCI of Naples 2003 President of Italian Melanoma Intergroup (IMI) 2004_2007 Member of International Melanoma Working Group (IMWG) 2006_2010 Member of Board Committee of Italian Network of Bioimmunologic Therapies (NIBIT) 2006_2012 Member of Provincial Technical Committee of Benevento for the application of the Regional Hospital Planning 2007_2009 Member of National Oncology Committee 2007_2008 President of Melanoma Foundation 2010_2015 President of Società Campana di Immunoterapia Oncologica (SCITO) 2014_to date Member of the Board of Society of Melanoma Research (SMR) 2016_to date Member of the Board of Cancer Development Drug Forum (CDDF) 2017_to February 2019 Member of Board of Directors for the Society of Immunotherapy of Cancer (SITC) 2018 to date Award "Premio Zanibelli 2018" as Person of the Year in the field of Healthcare and Cancer Research Lectures Invited speaker to more than 350 national and international scientific meetings, courses, and workshops. Peer_review of the following Scientific Journal: Journal of Clinical Oncology, The Lancet, British Journal of Dermatology, Cancer, Clinical Cancer Research, Cancer Research, Melanoma Research, Acta Dermato_Venereologica, Southern Medical Journal, Export Review of Molecular Diagnostics, Journal of Translational Medicine, Oncology Review, JEADV. Editorial Board of the following Scientific Journal: Annals of Oncology Section Editor for OncoImmunology Journal of Translational Medicine Section Editor for Combination Strategies Journal of Immunotherapy of Cancer Associate Editor Biomarker Research Editorial Board Member

Other Relevant Information